Comprehensive treatment regimens that combine PI3K inhibitors with other therapies, informed by metabolic and immune profiling of tumors, can address the diverse aspects of tumor biology, thereby enhancing therapeutic efficacy and minimizing resistance. Here, PIK3CB is linked to neoplasm.